🔥 Tune in to our new episode on maintenance therapy in #MultipleMyeloma with Hira Mian & Manni Mohyuddin ! We discuss a wide range of RCTs from CALGB to FORTE, ideal endpoints for maintenance trials, and role of MRD!
tinyurl.com/4mtjyz6m
Here is clip on Dara maint. in CASSIOPEIA!

👍🏽editorial by Angela Dispenzieri on FLC-Mass Spect in AL amyloidosis by awechalekar's group. I love the way Dr. Dispenzieri masterfully distills the key findings in one figure! A must-read and should be a benchmark for how to write an excellent commentary.
tinyurl.com/yjchc87z

Manni Mohyuddin Aaron Goodman - “Papa Heme” Comm onc here. COI: I'm a vegetarian. I tell my pts to eat/drink in moderation. For some, being able to do that is QoL. Grandma advice is good for now. Everything else is acad hubris unless some study shows otherwise. Vegan diets also cause time and financial tox in the community

Myeloma needs more therapy de-escalation trials. Won’t happen as long as pharma is running the show but we need to demand it. Do we really need duplicate single arm studies treating healthy people (smoldering myeloma)?

Important paper showing overall positive trend with 42% of first authors = female in 2019 (although wide range between countries).

Agree that WHY is the big question, so need to know what is the proportion of M vs. F oncologists in each country? How many are doing research and…

Tune in to our new episode on diagnosis and management of Essential Thrombocythemia with Raajit Rampal, M.D.Ph.D.!
tinyurl.com/yfzst3cw
Here is a clip on what to do with 'platelet millionaires'?
Ashwin Kishtagari, MD Eddie Cliff Raj Chakraborty
#mpnsm

Manni Mohyuddin Thank you Manni Mohyuddin , using agents with high risk of AEs that negatively affect quality of life in asymptomatic persons who may never develop cancer in a single arm study should not be allowed or accepted IMO

Deep down, even the proponents of invalid and untested surrogate endpoints, know that OS matters. That’s why there is (appropriate) celebration when a drug improves OS but I wonder where that acknowledgment of the importance of OS endpoint disappears when cheerleading marginal

100%

Imp. slide on the summary of trial-level correlation between MRD and PFS/OS across the disease spectrum in #Myeloma . IMO, key takeaway here is that MRD is NOT a good surrogate endpoint in most settings. (Ofc, has other utilities eg potential tool for Rx modification, prognosis)

With the FDA Oncology ODAC on #Myeloma MRD today, re-posting our episode on all things MRD with the MASTER Luciano J Costa!
Blood Cancer Talks Eddie Cliff Ashwin Kishtagari, MD
#mmsm #mmMRD

Check out my editorial: Clinical Trials of T-Cell Re-Directing Therapy in Plasma Cell Precursor Conditions #mmsm

➡️free access: authors.elsevier.com/a/1ivNN3QE--Z9…

Table 👇 with trials in MGUS&smoldering myeloma

I summarize reasons why such trials are problematic&can harm patients

4/

We report treatment patterns and preferred regimens post Dara-CyBorD failure

➡️ Median FU: 18 mos post D-VCd

➡️ 24% pts failed D-VCd

➡️ Median duration of D-VCd: 6 mos

➡️ trend for 1q21+ for higher failure rate (stay tuned for exciting data on this by Raj Chakraborty)

Out now in Leukemia Journal!

Treatment patterns for patients with AL amyloidosis post Dara CyBorD failure.

nature.com/articles/s4137…

Angela Dispenzieri Mayo Amyloid Shaji Kumar Vincent Rajkumar Morie Gertz Taxiarchis Kourelis Prashant Kapoor
Mayo Clinic Comprehensive Cancer Center Mayo Clinic Hematology-Oncology Fellowship

A brief 🧵 1/

If you have myeloma or its precursors and are on HealthTree Foundation, we'd love for you to complete a survey to help us understand pt preferences in settings where overall survival may be similar between treatment approaches

tinyurl.com/44nrxjd4

Eddie Cliff Raj Chakraborty

#mmsm

Public Service Announcement!

I urge all sub specialists to drop their IM board to avoid paying late fees. ABIM ties IM board to subspec board. Your subspec board cert depends on your IM board unless you deactivate it! Keeping it only results in pain

See what happened to me⬇️

With the recent ide-cel and cilta-cel approvals in earlier lines of therapy, re-upping our recent Blood Cancer Talks episode with Samer Al Hadidi, MD,MS,FACP where he distills the data presented at the recent FDA Oncology ODAC and we discuss how to pick the optimal therapy for a given patient

This is the kind of scenario where I would feel comfortable starting Dara-CyBorD without waiting for Mass Spect to come back (assuming there is monoclonal gammopathy)! Periorbital purpura and macroglossia = Highly specific for AL!